Clinical Characteristics and Follow-up of Complex Arrhythmias Associated with Gene Mutations in Children

Overview

Journal Front Genet

Date 2024 Jun 11

PMID 38859939

Authors

Yefeng Wang

Yufan Yang

Ningan Xu

Yunbin Xiao

Chao Zuo

Zhi Chen

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of this study was to analyze the diagnosis, treatment, and follow-up of six cases of complex arrhythmias associated with gene mutations in children.

Method: A retrospective analysis was conducted on six children diagnosed with complex arrhythmias associated with gene mutations. The study included an analysis of the age of onset, initial symptoms, electrocardiographic characteristics, genetic results, treatment course, and follow-up outcomes.

Results: Among the six cases included in the study, there were four males and two females, with an average age of 3.5 ± 0.5 years. The average time from initial symptoms to diagnosis was 2.7 ± 1.3 years. The most common clinical manifestation was syncope, with exercise and emotions being the main triggers. All six children had missense mutations in the gene identified through whole-exome sequencing. In Holter electrocardiogram, atrial arrhythmias and sinoatrial node dysfunction were commonly observed in younger children. Four patients underwent exercise stress testing, with two experiencing bidirectional ventricular premature contractions and two experiencing bidirectional ventricular tachycardia and polymorphic ventricular tachycardia. Initial treatment involved oral propranolol or metoprolol. If arrhythmias persisted, flecainide or propafenone was added as adjunctive therapy. Two patients received permanent cardiac pacemaker treatment (single chamber ventricular pacemaker, VVI). All patients survived, with three experiencing occasional syncope during treatment. The follow-up period ranged from 12 to 37 months, with an average follow-up time of 24.3 ± 3.7 months.

Conclusion: Complex arrhythmias associated with gene mutations in children can present with various clinical manifestations. Atrial arrhythmias combined with sinoatrial node dysfunction are commonly observed in younger children, and the combination of pharmacological therapy and cardiac pacemaker treatment yields favourable treatment outcomes.

References

Miyata K, Ohno S, Itoh H, Horie M . Bradycardia Is a Specific Phenotype of Catecholaminergic Polymorphic Ventricular Tachycardia Induced by RYR2 Mutations. Intern Med. 2018; 57(13):1813-1817. PMC: 6064684. DOI: 10.2169/internalmedicine.9843-17. View

Kawata H, Ohno S, Aiba T, Sakaguchi H, Miyazaki A, Sumitomo N . Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) Associated With Ryanodine Receptor (RyR2) Gene Mutations　- Long-Term Prognosis After Initiation of Medical Treatment. Circ J. 2016; 80(9):1907-15. DOI: 10.1253/circj.CJ-16-0250. View

Ohno S, Hasegawa K, Horie M . Gender Differences in the Inheritance Mode of RYR2 Mutations in Catecholaminergic Polymorphic Ventricular Tachycardia Patients. PLoS One. 2015; 10(6):e0131517. PMC: 4482545. DOI: 10.1371/journal.pone.0131517. View

Priori S, Wilde A, Horie M, Cho Y, Behr E, Berul C . Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes. Heart Rhythm. 2013; 10(12):e85-108. DOI: 10.1016/j.hrthm.2013.07.021. View

Bongianino R, Denegri M, Mazzanti A, Lodola F, Vollero A, Boncompagni S . Allele-Specific Silencing of Mutant mRNA Rescues Ultrastructural and Arrhythmic Phenotype in Mice Carriers of the R4496C Mutation in the Ryanodine Receptor Gene (). Circ Res. 2017; 121(5):525-536. DOI: 10.1161/CIRCRESAHA.117.310882. View

Medeiros-Domingo A, Bhuiyan Z, Tester D, Hofman N, Bikker H, van Tintelen J . The RYR2-encoded ryanodine receptor/calcium release channel in patients diagnosed previously with either catecholaminergic polymorphic ventricular tachycardia or genotype negative, exercise-induced long QT syndrome: a comprehensive open reading.... J Am Coll Cardiol. 2009; 54(22):2065-74. PMC: 2880864. DOI: 10.1016/j.jacc.2009.08.022. View

Kaneshiro T, Nogami A, Kato Y, Kuroki K, Komatsu Y, Tada H . Effects of Catheter Ablation Targeting the Trigger Beats in Inherited Catecholaminergic Polymorphic Ventricular Tachycardia. JACC Clin Electrophysiol. 2018; 3(9):1062-1063. DOI: 10.1016/j.jacep.2017.04.017. View

Shah M, Silka M, Avari Silva J, Balaji S, Beach C, Benjamin M . 2021 PACES Expert Consensus Statement on the Indications and Management of Cardiovascular Implantable Electronic Devices in Pediatric Patients: Developed in collaboration with and endorsed by the Heart Rhythm Society (HRS), the American College of.... JACC Clin Electrophysiol. 2021; 7(11):1437-1472. DOI: 10.1016/j.jacep.2021.07.009. View

Yamaguchi N, Zhang X, Morad M . CRISPR/Cas9 Gene Editing of RYR2 in Human iPSC-Derived Cardiomyocytes to Probe Ca Signaling Aberrancies of CPVT Arrhythmogenesis. Methods Mol Biol. 2022; 2573:41-52. DOI: 10.1007/978-1-0716-2707-5_4. View

10.

Al-Khatib S, Stevenson W, Ackerman M, Bryant W, Callans D, Curtis A . 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and.... J Am Coll Cardiol. 2017; 72(14):e91-e220. DOI: 10.1016/j.jacc.2017.10.054. View

11.

Wilde A, Semsarian C, Marquez M, Sepehri Shamloo A, Ackerman M, Ashley E . European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Europace. 2022; 24(8):1307-1367. PMC: 9435643. DOI: 10.1093/europace/euac030. View

12.

Faggioni M, van der Werf C, Knollmann B . Sinus node dysfunction in catecholaminergic polymorphic ventricular tachycardia: risk factor and potential therapeutic target?. Trends Cardiovasc Med. 2014; 24(7):273-8. PMC: 4171185. DOI: 10.1016/j.tcm.2014.07.001. View

13.

Kim C, Aronow W, Dutta T, Frenkel D, Frishman W . Catecholaminergic Polymorphic Ventricular Tachycardia. Cardiol Rev. 2020; 28(6):325-331. DOI: 10.1097/CRD.0000000000000302. View

14.

Kannankeril P, Shoemaker M, Gayle K, Fountain D, Roden D, Knollmann B . Atropine-induced sinus tachycardia protects against exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. Europace. 2020; 22(4):643-648. PMC: 7132542. DOI: 10.1093/europace/euaa029. View

15.

Perez-Riera A, Barbosa-Barros R, de Rezende Barbosa M, Daminello-Raimundo R, de Lucca Jr A, de Abreu L . Catecholaminergic polymorphic ventricular tachycardia, an update. Ann Noninvasive Electrocardiol. 2017; 23(4):e12512. PMC: 6931575. DOI: 10.1111/anec.12512. View

16.

Steinberg C, Roston T, van der Werf C, Sanatani S, Chen S, Wilde A . RYR2-ryanodinopathies: from calcium overload to calcium deficiency. Europace. 2023; 25(6). PMC: 10311407. DOI: 10.1093/europace/euad156. View

17.

Baltogiannis G, Lysitsas D, di Giovanni G, Ciconte G, Sieira J, Conte G . CPVT: Arrhythmogenesis, Therapeutic Management, and Future Perspectives. A Brief Review of the Literature. Front Cardiovasc Med. 2019; 6:92. PMC: 6644488. DOI: 10.3389/fcvm.2019.00092. View

18.

Kannankeril P, Moore J, Cerrone M, Priori S, Kertesz N, Ro P . Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial. JAMA Cardiol. 2017; 2(7):759-766. PMC: 5548393. DOI: 10.1001/jamacardio.2017.1320. View